# Phase 1/2 Head and Neck Neoplasms trials: 40 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 40 trials in phase 1/2 for Head and Neck Neoplasms that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1/2 Head and Neck Neoplasms trials: 40 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1-2/head-and-neck-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 40
- Recruiting or not yet: 40
- Read on: November 19, 2026

## Trials

The 25 newest of 40, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 14, 2026 | NCT07873450 | SumMET: Study of \[225Ac\]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET | Full-Life Technologies UK Limited | Phase 1/2 | Recruiting | Solid Tumor, NSCLC, Colorectal Cancer, Head and Neck Cancer, Cholangiocarcinoma | 208 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07873450) |
| September 1, 2026 | NCT07798414 | Randomized Clinical Trial of the Application of TrachPhone HME and the Impact on Patient Satisfaction for Tracheostomized Head and Neck... | University of South Florida | Phase 1/2 | Not yet recruiting | Patient Satisfaction, Pulmonary Rehabilitation | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07798414) |
| August 7, 2026 | NCT07752875 | A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation | LG Chem | Phase 1/2 | Not yet recruiting | Ovarian Cancer, Small Cell Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Esophageal Cancer, Breast... | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07752875) |
| July 15, 2026 | NCT07705074 | FAPI PET Imaging - An Exploratory Study | Sponsor not shown (see the record) | Phase 1/2 | Not yet recruiting | Thyroid Pathology, Head and Neck Cancer (H&N), Sinonasal Tract Tumor, Sarcoidosis, Thyroid Cancer, Breast Cancer... | 770 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07705074) |
| June 25, 2026 | NCT07667400 | Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer | National Cancer Institute (NCI) | Phase 1/2 | Recruiting | Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Paranasal Sinus Neoplasms, Nasopharyngeal Carcinoma... | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07667400) |
| June 23, 2026 | NCT07662681 | Camrelizumab With Famitinib for Patients With Rare Head and Neck Malignancies | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Phase 1/2 | Recruiting | Head and Neck Cancer | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07662681) |
| May 22, 2026 | NCT07601204 | Treatment of Recurrent/Metastatic Head and Neck Cancer | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | Phase 1/2 | Not yet recruiting | Recurrent/Metastatic Head and Neck Cancer | 128 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07601204) |
| April 27, 2026 | NCT07552558 | Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC) | Washington University School of Medicine | Phase 1/2 | Not yet recruiting | Head and Neck Squamous Cell Carcinoma, HPV-Negative Squamous Cell Carcinoma | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07552558) |
| April 20, 2026 | NCT07538206 | Vebectotamab Vedotin Combined With Pucotelimab in the Treatment of Locally Advanced Laryngeal Carcinoma | Tang-Du Hospital | Phase 1/2 | Not yet recruiting | Head & Neck Cancer | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07538206) |
| February 12, 2026 | NCT07407582 | Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS) | University of Arizona | Phase 1/2 | Recruiting | Solid Tumor Malignancies, Testicular Cancer, Head and Neck Cancer, Thoracic Cancer | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07407582) |
| January 14, 2026 | NCT07341737 | SL-28 for Advanced Solid Tumours | Second Life Therapeutics | Phase 1/2 | Recruiting | Head & Neck Cancer, Pancreas Carcinoma, Pancreas Cancer, Metastatic, Lung Adenocarcinoma, Lung Cancer (NSCLC), Lung... | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07341737) |
| January 14, 2026 | NCT07339176 | Intratumoral N17350 in Advanced Solid Tumors | Onchilles Pharma Inc | Phase 1/2 | Recruiting | Neoplasms, Solid Tumor, Breast Neoplasms, Triple-Negative, Squamous Cell Carcinoma of Skin, Melanoma, Head and Neck... | 275 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07339176) |
| December 18, 2025 | NCT07292168 | A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast... | Kidney Cancer Research Bureau | Phase 1/2 | Recruiting | Renal Cell Carcinoma Metastatic, Prostate Cancer Metastatic, Non-small Cell Lung Cancer Metastatic, Breast Cancer... | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07292168) |
| October 9, 2025 | NCT07213934 | Phase I/ II Trial Combining PD-1 Inhibition and Neoadjuvant Proton or Photon Radiation Therapy in Recurrent Head and Neck Squamous Cell... | University of Cincinnati | Phase 1/2 | Recruiting | Head and Neck Cancer, Recurrent Head and Neck Squamous Cell Carcinoma | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07213934) |
| September 18, 2025 | NCT07180576 | The FORCE Trial Pilot: Fish Oil-enriched Nutrition for Radiotherapy in Cancer of the hEad and Neck | Sponsor not shown (see the record) | Phase 1/2 | Not yet recruiting | Head &Amp;Amp; Neck Squamous Cell Carcinoma | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07180576) |
| May 29, 2025 | NCT06993844 | Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors | Ensem Therapeutics | Phase 1/2 | Recruiting | Advanced Solid Tumors, Advanced Breast Cancer | 233 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06993844) |
| November 29, 2024 | NCT06710756 | Lead-212 PSV359 Therapy for Patients With Solid Tumors | Perspective Therapeutics | Phase 1/2 | Recruiting | Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Esophageal Cancer, Colorectal Cancer, Ovarian Cancer, Head and Neck... | 112 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06710756) |
| October 24, 2024 | NCT06657222 | First in Human Study of TUB-030 in Patients With Advanced Solid Tumors | Gilead Sciences | Phase 1/2 | Recruiting | Advanced Solid Tumors, HNSCC, SCLC, NSCLC, TNBC - Triple-Negative Breast Cancer, CRC | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06657222) |
| August 12, 2024 | NCT06549946 | Ixovex-1 Single Agent and Combination Therapy | Psivac Ltd | Phase 1/2 | Recruiting | Solid Tumor, Head and Neck Cancer | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06549946) |
| July 17, 2024 | NCT06505551 | Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma | SCG Cell Therapy Pte. Ltd. | Phase 1/2 | Not yet recruiting | HPV-Related Squamous Cell Carcinoma, HPV-Related Cervical Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell... | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06505551) |
| July 10, 2024 | NCT06494943 | Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCC | Fudan University | Phase 1/2 | Recruiting | Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06494943) |
| March 20, 2024 | NCT06319963 | A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer | Theravectys S.A. | Phase 1/2 | Recruiting | HPV-Related Cervical Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06319963) |
| February 20, 2024 | NCT06265025 | GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors | GeneMedicine Co., Ltd. | Phase 1/2 | Recruiting | Head and Neck Cancer, Malignant Melanoma, Colorectal Cancer, Renal Cell Carcinoma, Cervical Cancer, Breast Cancer | 125 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06265025) |
| February 2, 2024 | NCT06239194 | Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors | ModeX Therapeutics, An OPKO Health Company | Phase 1/2 | Recruiting | Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Endometrial Cancer, Esophageal Cancer, Gastric... | 330 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06239194) |
| July 13, 2023 | NCT05944237 | HTL0039732 in Participants With Advanced Solid Tumours | Cancer Research UK | Phase 1/2 | Recruiting | Neoplasms, Prostatic Neoplasms, Castration-Resistant, Stomach Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms... | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05944237) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Onchilles Pharma Inc | 1 |
| Kidney Cancer Research Bureau | 1 |
| Coordination Pharmaceuticals, Inc. | 1 |
| PMV Pharmaceuticals, Inc | 1 |
| Psivac Ltd | 1 |
| Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | 1 |
| Washington University School of Medicine | 1 |
| Perspective Therapeutics | 1 |
| Inhibrx Biosciences, Inc | 1 |
| University of Cincinnati | 1 |
| Cancer Research UK | 1 |
| Turning Point Therapeutics, Inc. | 1 |
| Erasmus Medical Center | 1 |
| Second Affiliated Hospital of Guangzhou Medical University | 1 |
| [Betta Pharmaceuticals Co., Ltd.](https://specstream.ai/data/clinical-trials/company/betta-pharmaceuticals-co-ltd) | 1 |
| ModeX Therapeutics, An OPKO Health Company | 1 |
| GeneMedicine Co., Ltd. | 1 |
| Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 1 |
| VM Oncology, LLC | 1 |
| LigaChem Biosciences, Inc. | 1 |
| National Cancer Institute (NCI) | 1 |
| Marengo Therapeutics, Inc. | 1 |
| University of Arizona | 1 |
| SCG Cell Therapy Pte. Ltd. | 1 |
| Maastricht University Medical Center | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 22 |
| China | 8 |
| Australia | 6 |
| France | 6 |
| Spain | 6 |
| South Korea | 4 |
| United Kingdom | 4 |
| Canada | 4 |
| Netherlands | 4 |
| Germany | 3 |
| Italy | 3 |
| Singapore | 3 |
| Belgium | 3 |
| Taiwan | 2 |
| Japan | 2 |
| Russia | 1 |
| Denmark | 1 |
| Hong Kong | 1 |
| Hungary | 1 |
| Poland | 1 |
| Puerto Rico | 1 |
| Switzerland | 1 |
| Ireland | 1 |
| Romania | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [TV service providers in the United States](https://specstream.ai/data/businesses/tv-service-providers/united-states)
- [Laser cutting companies in the United States](https://specstream.ai/data/businesses/laser-cutting-companies/united-states)
- [Business office supplies and stationery companies in the United States](https://specstream.ai/data/businesses/business-office-supplies-and-stationery-companies/united-states)
- [Remodeling contractors in the United States](https://specstream.ai/data/businesses/remodeling-contractors/united-states)
- [Freight forwarders in the United States](https://specstream.ai/data/businesses/freight-forwarders/united-states)
- [Allergy and immunology practices in the United States](https://specstream.ai/data/businesses/allergy-and-immunology-practices/united-states)
